

Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/EDB2EDB4D4D8EN.html>

Date: April 2021

Pages: 62

Price: US\$ 125.00 (Single User License)

ID: EDB2EDB4D4D8EN

Abstracts

Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company's marketed products include: Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company's pipeline product candidates include XL092 for the treatment of advanced solid malignancies and XL888, an ATP-competitive inhibitor of HSP90, and others. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.

Exelixis Inc Key Recent Developments

Feb 19,2021: Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021

Feb 10,2021: Exelixis announces fourth quarter and full year 2020 financial results and provides corporate update

Jan 10,2021: Exelixis announces preliminary fourth quarter and full year 2020 financial results, provides 2021 financial guidance, and outlines key priorities and anticipated

milestones for 2021

Nov 05,2020: Exelixis announces third quarter 2020 financial results and provides corporate update

Aug 06,2020: Exelixis announces second quarter 2020 financial results and provides corporate update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage,

financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

- Exelixis Inc - Key Facts
- Exelixis Inc - Key Employees
- Exelixis Inc - Key Employee Biographies
- Exelixis Inc - Major Products and Services
- Exelixis Inc - History
- Exelixis Inc - Company Statement
- Exelixis Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

- Company Overview
- Exelixis Inc - Business Description
- Product Category: Collaboration Revenues
- Overview
- Performance
- Product Category: Net Product Revenues
- Overview
- Performance
- Geographical Segment: Europe
- Performance
- Geographical Segment: Japan
- Performance
- Geographical Segment: United States
- Performance
- Exelixis Inc - Corporate Strategy
- Exelixis Inc - SWOT Analysis
- SWOT Analysis - Overview
- Exelixis Inc - Strengths
- Exelixis Inc - Weaknesses
- Exelixis Inc - Opportunities
- Exelixis Inc - Threats
- Exelixis Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Exelixis Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 19, 2021: Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021

Feb 10, 2021: Exelixis announces fourth quarter and full year 2020 financial results and provides corporate update

Jan 10, 2021: Exelixis announces preliminary fourth quarter and full year 2020 financial results, provides 2021 financial guidance, and outlines key priorities and anticipated milestones for 2021

Nov 05, 2020: Exelixis announces third quarter 2020 financial results and provides corporate update

Aug 06, 2020: Exelixis announces second quarter 2020 financial results and provides corporate update

May 05, 2020: Exelixis announces first quarter 2020 financial results and provides corporate update

Apr 21, 2020: Exelixis to Release First Quarter 2020 Financial Results on Tuesday, May 5, 2020

Mar 03, 2020: Exelixis announces George A. Scangos, Ph.D. to retire from its Board of Directors

Feb 25, 2020: Exelixis announces fourth quarter and full year 2019 financial results and provides corporate ...

Jan 12, 2020: Exelixis outlines key priorities and anticipated milestones for 2020-21, announces preliminary fourth quarter and full year 2019 financial results, and provides 2020 financial guidance

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Exelixis Inc, Key Facts
Exelixis Inc, Key Employees
Exelixis Inc, Key Employee Biographies
Exelixis Inc, Major Products and Services
Exelixis Inc, History
Exelixis Inc, Subsidiaries
Exelixis Inc, Key Competitors
Exelixis Inc, Ratios based on current share price
Exelixis Inc, Annual Ratios
Exelixis Inc, Annual Ratios (Cont...1)
Exelixis Inc, Annual Ratios (Cont...2)
Exelixis Inc, Interim Ratios
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Exelixis Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Exelixis Inc, Performance Chart (2016 - 2020)

Exelixis Inc, Ratio Charts

Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/EDB2EDB4D4D8EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EDB2EDB4D4D8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970